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Abstract: Retroperitoneal lymph node dissection (RPLND) can been employed as primary treatment for
stage I non-seminomatous germ cell tumor (NSGCT) as well as for treatment of post-chemotherapy masses.
Open RPLND (O-RPLND) has long been the standard approach for lymphadenectomy, but is associated
with significant morbidity. Laparoscopic RPLND (L-RPLND) was developed to mitigate the morbidity
associated with O-RPLND, but is a technically challenging procedure requiring significant experience with
laparoscopic dissection and suturing to remove lymph nodes behind the great vessels and to control vascular
injury. Robotic RPLND (R-RPLND) has gained traction in recent years as an alternative to both O-RPLND
and L-RPLND. With superior instrument dexterity and better visualization compared to L-RPLND, and
with decreased morbidity, compared to O-RPLND, R-RPLND can be performed safely and effectively.
With the latest advances in robotic technology, one can perform a full bilateral dissection without needing to
reposition the patient or redock the robot. R-RPLND has been applied for both primary treatment as well as
in patients with post-chemotherapy residual abdominal masses.
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Introduction
Testicular cancer is typically a disease of young men (1) with
multiple available treatment options. Therapeutic pathways
depend on disease stage and pathologic features and
typically result in high survival rates. Treatments include
active surveillance, retroperitoneal lymph node dissection
(RPLND), primary chemotherapy, and radiotherapy
(seminoma only) (2) and choice of therapy is often based
on the patient’s perception of treatment toxicities. Surgery
has typically been utilized as primary treatment for clinical
stage (CS) I non-seminomatous germ cell tumor (NSGCT)
as well as for post-chemotherapy residual masses.
When considering a surgical approach, open RPLND

© Translational Andrology and Urology. All rights reserved.

(O-RPLND) has been long considered the standard of
care and the basis for comparison of alternative surgical
techniques. Access for O-RPLND, however, historically has
involved a xiphoid to pubis abdominal wall incision to allow
access to the entire retroperitoneum and can be associated
with significant morbidity. Given the pain and morbidity
associated with this incision many young men choose
chemotherapy as primary treatment for CS I NSGCT
despite its significant toxicities (3,4).
Laparoscopic RPLND (L-RPLND) was introduced in
1992 as an alternative to O-RPLND (5) and was utilized in
patients with CS I and low volume CS II disease. Compared
to O-RPLND, L-RPLND resulted in significantly
decreased morbidity, however, given that the majority of
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patients undergoing L-RPLND had lower lymph node
yields (6), and those found to have positive retroperitoneal
lymph nodes received adjuvant chemotherapy, it was mostly
considered a staging procedure (7). Additionally, L-RPLND
is a challenging operation with difficulty accessing the
lymph nodes posterior to the great vessels and controlling
vascular bleeding. It was thus limited only to a few centers
of excellence with expert laparoscopic surgeons.
Robotic surgery is an alternative minimally invasive
surgical technique resulting in the benefit of decreased
surgical morbidity associated with laparoscopic surgery
while providing improved visualization, instrument
dexterity and ergonomics. R-RPLND was first performed
in 2006 (8), and since then, multiple investigators have
demonstrated it to be a viable and safe surgical approach
(9-11). With R-RPLND, there is improved capability
to dissect behind the great vessels and to more easily
control major bleeding. As experience with R-RPLND has
improved, it has transformed a minimally invasive approach
to RPLND from a staging operation to a therapeutic one.
Indications and staging for R-RPLND
Patients with suspected testicular cancer should routinely
have tumor markers drawn prior to orchiectomy,
including alpha fetal protein (AFP), beta-human chorionic
gonadotropin (B-HCG), and lactate dehydrogenase
(LDH). Axial imaging of the chest, abdomen, and pelvis is
performed with computed tomography (CT) scan. Based on
orchiectomy pathology results, tumor markers, and imaging
findings, the appropriate clinical stage can be determined.
R-RPLND can be employed as primary treatment
for patients with tumor marker negative, high-risk, CS I
NSGCT. Those with pathology specimens demonstrating
lymphovascular invasion or greater than 50% embryonal
carcinoma in the orchiectomy specimen are considered
high risk. Patients with low risk CS I NSGCT are best
managed with active surveillance. Some investigators are
also exploring the use of RPLND as primary treatment for
low-stage seminoma, however, the results of this are yet to
be determined (12). Patients with tumor marker negative
CS IIA NSGCT and certain cases of CS IIB NSGCT may
be eligible for primary treatment with R-RPLND (2).
Additionally, NSGCT patients with post-chemotherapy
masses larger than 1 cm and negative tumor markers
are candidates for R-RPLND (2). Patients with post
chemotherapy masses obstructing the inferior vena cava
which may require vascular replacement are best managed
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with an open approach.
Operative technique and perioperative
management
After full pre-operative assessment and appropriate
patient counseling has been completed, informed
consent is obtained and if the patient is under 18 years
of age, parental consent is necessary. Potential risks of
the procedure that are discussed include major vascular
injury requiring repair or vascular surgery consultation,
bowel injury, nephrectomy, deep venous thrombosis with
pulmonary embolus, lymphatic fluid leakage including
chylous ascites, and ejaculatory dysfunction. Patients are
routinely counseled to back sperm prior to R-RPLND.
Patients undergo a modified bowel preparation with a clear
liquid diet and magnesium citrate starting 24 hours prior
to surgery. Induction of general anesthesia is performed
with deep paralysis to allow for full pneumoperitoneum.
Mechanical and chemical deep vein thrombosis prophylaxis
is given with placement of sequential compression
devices and subcutaneous injection of unfractionated or
low molecular weight heparin. Perioperative antibiotics,
typically a cephalosporin, are administered within
30 minutes of incision time. An orogastric tube is placed to
decompress the stomach and a urethral catheter is inserted
to decompress the bladder and keep track of urine output.
Room set-up and patient positioning
Our technique for R-RPLND is via a supine approach. We
find that this allows for a complete, bilateral dissection if
needed. Both the da Vinci (Intuitive Surgical; Sunnyvale,
CA) Si and Xi platforms can be utilized, although, the Xi
is our preferred platform as it allows multi-quadrant access
without the need to redock the robot.
The patient is placed supine on a full torso gel pad
which prevents patient movement when placed in the
Trendelenburg position. Arms are padded and tucked and
legs are supported. A Veress needle is used to gain entry
at Palmer’s point (subcostal margin left upper quadrant)
and establish pneumoperitoneum. If the da Vinci Si model
is being used, a 12-mm trocar is placed 3–4 cm below the
umbilicus in the midline. A 0-degree camera is used to place
the remaining ports under direct vision. An 8-mm right
robotic port and 4th arm port is placed on the patient’s left
side and an 8 mm left robotic port is placed on the patient’s
right side. A 12-mm assistant port is placed between
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Figure 1 da Vinci Si port placement configuration. The small “o”
represents an 8-mm trocar. The large “X” represents a 12-mm
trocar.

Figure 2 da Vinci Xi port placement configuration. The small “o”
represents an 8-mm trocar. The large “X” represents a 12-mm
trocar.

the camera port and the left robotic port (Figure 1). As
demonstrated in the figure, all arms are placed caudad to the
level of the umbilicus in an off-set fashion, thus facilitating
cephalad dissection. There should be at least 7 cm of space
between ports to prevent external arm collisions. For the
Xi model, a linear port configuration is utilized using four
robot 8 mm ports and a 12 mm assistant port (Figure 2).
These ports are placed at least 6–7 cm apart. A 0-degree
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lens is utilized initially to gain access to the retroperitoneum
but later switch to a 30-degree down lens during lymphatic
dissection. We routinely use the Air Seal (Conmed; Utica,
New York, USA) insufflation device is used to maintain
pneumoperitoneum at 12 mmHg. The patient is placed in
20–30 degrees Trendelenburg position to allow the small
intestine to fall cephalad and the robot is docked.
The assistant is usually placed on the patient’s right side
and scrub nurse will be on the patient’s left side. A Mayo
stand will be positioned between the patient’s legs and will
hold laparoscopic and robotic instruments commonly used
throughout the case. If utilizing the da Vinci Si model,
the robot is brought from the head of the bed over the
left shoulder. The entire retroperitoneal dissection can
be performed from this docking location except for the
removal of the spermatic cord within the inguinal canal.
Removal of the spermatic cord requires re-docking of the
da Vinci Si at the end of the case alongside the patient’s
ipsilateral leg with the ports redirected towards the internal
inguinal ring. Docking can be from any direction with the
da Vinci Xi due to the rotating boom, but our routine is
to dock on the side opposite the bedside assistant. It does
not need to be redocked to excise the spermatic cord as
it is designed to allow for extended reach of its arms thus
providing multi-quadrant access.
A 0-degree camera is used initially to gain retroperitoneal
exposure, but is later changed to a 30 degree down lens
for node dissection. Our instruments of choice include a
monopolar scissors, a fenestrated bipolar, and a Progasp
grasper for the 4th arm. If vascular injury is encountered,
we use robotic needle drivers. Two additional instruments
that are very helpful for R-RPLND include a robotic clip
applier, which allows control of lymphatics not able to be
reached by the assistant, and a robotic vessel sealer, which is
ideal for controlling lumbar vessels.
The bedside assistant will have access to a suctionirrigation device, laparoscopic clip appliers (for both
titanium and polymer clips), graspers, and laparoscopic
needle drivers to aid in passing stitches to the surgeon.
“Rescue stitches” are created beforehand in case urgent
vascular control is required. We favor a 4-0 polypropylene
suture cut to 12 cm with a small absorbable clip at the
end. An endocatch bag is utilized to remove the lymphatic
specimens as they are freed.
Dissection technique
Access is gained to the retroperitoneum by incising the
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Figure 5 Clipping lymphatics, especially those overlying the
left renal vessels as pictured above, is paramount to preventing a
Figure 3 Suture suspension of the right peritoneal cut edge to the

chylous leak. IVC, inferior vena cava.

right abdominal wall.

Figure 4 The renal vessels represent the upper limit of template
dissection. IVC, inferior vena cava.

posterior peritoneum just medial to the cecum extending to
the ligament of Treitz. We typically create a hammock-like
barrier by suturing both cut ends of the parietal peritoneum
to the anterior abdominal wall. We typically use a 3-0
monofilament suture and secure it with polymer clips
(Figure 3). This, along with the patient’s Trendelenburg
position, acts to retract the small bowel away from the field,
allowing visualization of the distal lower retroperitoneum.
The duodenum is identified and carefully mobilized, if
needed, and then gently retracted cephalad utilizing the
Prograsp. This creates the upper retroperitoneal exposure
needed to allow for a full dissection.
For both right-sided and left-sided template dissections,
the ipsilateral renal vessels represent the upper limit
of dissection (Figure 4). The inferior mesenteric artery
(typically spared) and the ipsilateral ureteral crossing over
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the common iliac vessels represent, respectively, the inferior
medial and inferior lateral limits of dissection. A right-sided
template dissection entails removal of paracaval, precaval,
retrocaval, interaortocaval, and paraaortic nodal packets.
A left-sided template dissection includes removal of the
paraaortic, preaortic, retroaortic, and interaortocaval nodal
packets. A full, bilateral template dissection combines both
right-sided and left-sided templates.
A split-and-roll technique is utilized to remove all lymph
nodes and allows good access to retrocaval and retroaortic
nodal tissue. Polymer clips are placed on lymphatic channels
for node removal and can be placed by the bedside assistant
or the surgeon via a robotic clip applier. We always ensure
precise control of the lymphatics crossing over the left renal
vein as well as the cisterna chyli between the inferior vena
cava and aorta in order to prevent chylous ascites (Figure 5).
The inferior mesenteric artery is typically preserved
but can be sacrificed if needed. We routinely perform a
nerve-sparing operation to prevent retrograde ejaculation
especially in post chemotherapy patients requiring a
bilateral dissection. Sympathetic post-ganglionic nerve
fibers can be identified at their origin at the sympathetic
chain. These are traced to the hypogastric plexus overlying
the distal aorta. Care is taken not to use electrocautery
along the nerves and nerve fibers to prevent inadvertent
thermal injury.
If R-RPLND is being performed for CS I NSGCT,
typically a unilateral template dissection is performed.
Lymph nodes are sent for frozen analysis and, if positive, a
full bilateral template dissection is completed. If R-RPLND
is being performed for a post-chemotherapy residual mass,
a full bilateral template dissection is always undertaken
(Figure 6). All specimens should be placed in endoscopic
retrieval bags, which are removed at the end of the case.
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Figure 6 View of the great vessels after nodal dissection is
complete. In the case above, the tumor was noted to be invading
into the inferior vena cava requiring cavotomy and ultimately
repair with a 4-0 prolene stitch. IVC, inferior vena cava.

Spermatic cord excision is lastly performed with
dissection carried out caudally. If the da Vinci Si is used, redocking is needed along the patient’s ipsilateral leg. There
is no re-docking needed for the da Vinci Xi. Dissection is
performed out of the internal inguinal ring until sutures
from the prior radical orchiectomy are seen. These, along
with the entire cord stump, are removed.
Post-operative management
Post-operatively, patients are placed on a clear liquid diet,
which is advanced as tolerated to a low-fat diet (<20 grams
of fat). This low-fat diet is continued for two weeks after
the operation to minimize the risk of chylous ascites.
Chylous ascites, should it develop, is typically managed with
bowel rest and total parenteral nutrition. Should this not
resolve, then procedural or operative intervention should
be considered. Patients should also bank sperm prior to
surgery in the event of retrograde ejaculation.
Discussion
As experience with R-RPLND has increased, it has been
utilized as primary treatment for low-stage NSGCT
(9,10) and for post-chemotherapy masses (13). Pearce
et al. (14) had the largest study examining outcomes of
primary R-RPLND in patients with CS I–IIA NSGCT.
Six surgeons at four different institutions, over a 5-year
period, performed R-RPLND on 47 patients, of which
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42 had CS I disease. The median operative time was
235 minutes and the median estimated blood loss (EBL) was
50 mL. Risk factors for the retroperitoneal disease included
lymphovascular invasion and involvement of embryonal
carcinoma in greater than 40% of the orchiectomy
specimen. The median lymph node count was 26 nodes and
the median length of stay (LOS) was one day. Intraoperative
complications included a vascular injury requiring open
repair and a pancreatic injury that resolved with drain
placement and non-operative management. Complications
within the first 30 days included two Clavien grade I
complications and two Clavien grade III complications,
which included a large body-wall hematoma requiring
transfusion and chylous ascites requiring paracentesis. Eight
of the 42 patients ultimately had node positive disease, with
seven or these patients with pN1 disease and the remaining
patient with pN2 disease. Five of these patients received
adjuvant chemotherapy with the remaining three managed
with surveillance. The 2-year recurrence-free survival rate
was 97% overall (100% in patients not treated with adjuvant
chemotherapy), however, the median follow-up was only
6 months, constituting a major limitation of this study (14).
The largest single institution study was previously
published by our group in 2016 and examined R-RPLND
utilizing both the lateral and supine approaches (11). The
study included 19 patients that underwent 20 procedures,
16 of which were primary R-RPLND with the remaining
four post-chemotherapy R-RPLND. Median operative
time was 293 minutes and median EBL was 50 mL. The
median lymph node count was 19.5 and the median LOS
was one day with the vast majority of patients discharged
within 24 hours of surgery. There was one intraoperative
complication involving a recognized ureteral transection
that was primarily repaired without long-term sequelae.
No patients requiring blood transfusion. There were no
major post-operative complications although two of the
patients who underwent post-chemotherapy full template
R-RPLND did experience retrograde ejaculation. Eight of
the 19 patients ultimately were found to have pathologic
stage II disease with three of these patients having teratoma.
Only two patients received adjuvant chemotherapy,
including one patient with pathologic stage IIC disease and
another that developed a lung recurrence four months after
RPLND. The remaining pathologic stage II patients were
kept under surveillance with no evidence of recurrence at
follow-ups of 46, 47, and 91 months, respectively (11).
Tselos et al. performed a systematic review of 11 studies
examining a total of 116 patients (15). The mean operative
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time was 263 minutes and the median lymph node count
was 22.3. The complication rate was 8%, with half of these
designated minor complications (Clavien grade I–II) and
the other half major complications (Clavien grade III–IV).
Retrograde ejaculation was seen in 4.5% of patients. The
median length of stay was 1.3 days and the average followup at 21.2 months demonstrated no evidence of disease
recurrence (15).
The length of stay for all R-RPLND studies detailed
above was better than those reported for O-RPLND
(ranging from 3 days, at very high-volume institutes, to
6.6 days) (6,16-18) and for L-RPLND (2.6 to 3.3 days)
(6,19). Like L-RPLND (204 to 258 min) (6,19), R-RPLND
has a longer operative time (235 to 293 min) compared
to O-RPLND (132 min at very high volume institutions,
otherwise reported 186 to 270 min) (6,16-18).
Intraoperative complication rates have been reported
for O-RPLND to range from 5–7% (16,17) with a
6% transfusion rate (17). EBL is typically higher than
R-RPLND, with reported rates of 184 to 450 mL (6,16-18).
Post-operative complication rates have been reported as
high as 24% (17) with some data suggesting an all-comer
overall complication rate of 33% (6).
Laparoscopic complication rates have been reported as
high as 15.6% with a conversion rate of 3.8% (6) with most
conversion rates due to bleeding and inability to control
it laparoscopically. Long term oncologic outcomes after
laparoscopic surgery, as a primary therapeutic modality,
have been confounded with the high percentage of patients
who have chemotherapy after positive nodes are discovered
after surgery (20). The quality of life in patients who had
L-RPLND, however, has been shown to be significantly
higher than those patients who underwent O-RPLND (21).
There have been studies primarily looking at the
feasibility of R-RPLND for post-chemotherapy patients
as well. The major challenge with post-chemotherapy
RPLND stems from significant fibrosis of the
retroperitoneal mass causing adhesion to the great vessels.
This creates an environment for possible vascular injury
that could require urgent control. Singh et al. published
the largest single institution series for post-chemotherapy
R-RPLND involving 13 patients. The vast majority of
these patients had a unilateral modified template dissection
with a lateral approach. The median operative time was
200 minutes and median EBL was 120 mL. The median
lymph node count was 20 and median LOS was four days.
The only intraoperative complication was an aortic injury
that was repaired robotically. Post-operatively, four patients
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developed chylous ascites (two of whom required operative
repair) and five patients developed an ileus. Pathology
demonstrated that three patients had teratoma and the
remaining eight had necrosis. There was no evidence of
disease recurrence at a median follow-up of 23 months (22).
Overs et al. reviewed 11 post-chemotherapy patients who
underwent unilateral modified template R-RPLND via a
lateral approach. Median operative time was 150 minutes
and median EBL was 120 mL. The median lymph
node count was seven and the majority of patients
were discharged on hospital day three. There were no
intraoperative complications reported. Post-operatively, one
patient developed chylous ascites that was managed nonoperatively. Over 70% of men retained ejaculatory function.
Long-term follow-up was only available for six patients
and none had evidence of recurrence at 24 months (23).
Both studies highlight the feasibility of performing postchemotherapy RPLND robotically. Critics may argue that,
per NCCN guidelines, a full bilateral template dissection
should be undertaken in the setting of residual postchemotherapy masses (2). A supine approach, as described
earlier, would allow for better access for a full template
dissection without the need for re-docking, and should be
considered.
Operative time for R-RPLND for the above-mentioned
studies is less than for O-RPLND (226 to 305 min)
(16,17,24) and is on-par, if not somewhat faster, than for
L-RPLND (183 to 213 min) (24-26). One has to consider,
however, that both for R-RPLND and L-RPLND, most of
these cases involved a modified template dissection on not
a full bilateral template dissection. EBL was higher in both
O-RPLND (413 to 1,000 mL) (16,17) with transfusion rates
ranging from 14.2% to 42% (17,24). Complication rates
have been reported to range from 12% to 38% (16,17,24).
L-RPLND had EBL ranging from 260 to 400 mL (25,26)
with conversion rates reported as high as 11.5% (26), which
are more than the above mentioned rates for R-RPLND.
LOS for O-RPLND varied based on institution anywhere
from 4.8 #to 11.5 days (16,17,24) and 5–6 days for
L-RPLND (24,26). The complexity of cases varied based
on institutional experience and operative approach, and thus
these factors must always be considered when determining
how to treat patients.
Conclusions
R-RPLND has developed into a safe and effective
approach for primary management of low stage NSGCT.
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In experienced hands, and with judicious patient selection,
it can also be utilized with good effect for management of
post-chemotherapy residual NSGCT masses. However,
for large, bulky residual disease, R-RPLND may prove a
challenge and one must employ caution in approaching
these types of cases robotically. As expertise grows,
techniques will continue to evolve. Our experience has
demonstrated that a supine approach allows for superior
retroperitoneal access facilitating full, bilateral template
dissection. It is the preferred approach for both primary and
post-chemotherapy R-RPLND. Ultimately, more studies
with longer-term follow-up directly comparing R-RPLND
to O-RPLND are needed to effectively compare clinical
efficacy relative to complications.

5.

6.

7.

8.

9.

Acknowledgments
All figures have been used with permission from “New
Technologies and Techniques in Minimally Invasive
Urologic Surgery: an ESUT Collection (2019)”.

10.

Footnote
Conflicts of Interest: JR Porter: Speaker for Intuitive Surgical,
Consultant for Ceevra, C-SATS advisory board. HR
Mittakanti has no conflicts of interest to declare.

11.

Ethical Statement: The authors are accountable for all
aspects of the work in ensuring that questions related
to the accuracy or integrity of any part of the work are
appropriately investigated and resolved.

12.

13.

References
1.

2.

3.

4.

Noone AM, Krapcho M, Miller D, et al. SEER Cancer
Statistics Review, 1975-2015. Bethesda, MD: National
Cancer Institute, 2018.
Motzer RJ, Agarwal N, Beard C, et al. National
Comprehensive Cancer Network Clinical Practice
Guidelines in Oncology: testicular Cancer. J Natl Compr
Canc Netw 2009;7:672-93.
Tandstad T, Stahl O, Hakansson U, et al. One course of
adjuvant BEP in clinical stage I nonseminoma mature and
expanded results from the SWENOTECA group. Ann
Oncol 2014;25:2167-72.
Haugnes HS, Bosl GJ, Boer H, et al. Long-term and
late effects of germ cell testicular cancer treatment and
implications for follow-up. J Clin Oncol 2012;30:3752-63.

© Translational Andrology and Urology. All rights reserved.

14.

15.

16.

17.

Rukstalis DB, Chodak GW. Laparoscopic retroperitoneal
lymph node dissection in a patient with stage 1 testicular
carcinoma. J Urol 1992;148:1907-9; discussion 1909-10.
Rassweiler JJ, Scheitlin W, Heidenreich A, et al.
Laparoscopic retroperitoneal lymph node dissection: does
it still have a role in the management of clinical stage I
nonseminomatous testis cancer? A European perspective.
Eur Urol 2008;54:1004-15.
Nielsen, ME, Lima G, Schaeffer EM, et al. Oncologic
efficacy of laparoscopic RPLND in treatment of clinical
stage I nonseminomatous germ cell testicular cancer.
Urology 2007;70:1168-72.
Davol P, Sumfest J, Rukstalis D, et al. Robotic-assisted
laparoscopic retroperitoneal lymph node dissection.
Urology 2006;67:199.
Williams SB, Lau CS, Josephson DY. Initial series of
robot-assisted laparoscopic retroperitoneal lymph node
dissection for clinical stage I nonseminomatous germ cell
testicular cancer. Eur Urol 2011;60:1299-302.
Cheney SM, Andrews PE, Leibovich BC, et al. Robotassisted retroperitoneal lymph node dissection:
technique and initial case series of 18 patients. BJU Int
2015;115:114-20.
Stepanian S, Patel M, Porter JR. Robot-assisted
Laparoscopic Retroperitoneal Lymph Node Dissection for
Testicular Cancer: Evolution of the Technique. Eur Urol
2016;70:661-7.
Hu B, Daneshmand S. Retroperitoneal Lymph Node
Dissection as Primary Treatment for Metastatic
Seminoma. Adv Urol 2018;2018:7978958.
Kamel MH, Littlejohn N, Cox M, et al. PostChemotherapy Robotic Retroperitoneal Lymph Node
Dissection: Institutional Experience. J Endourol
2016;30:510-9.
Pearce SM, Golan S, Gorin MA, et al. Safety and
Early Oncologic Effectiveness of Primary Robotic
Retroperitoneal Lymph Node Dissection for
Nonseminomatous Germ Cell Testicular Cancer. Eur
Urol 2017;71:476-82.
Tselos A, Moris D, Tsilimigras DI, et al. Robot-Assisted
Retroperitoneal Lymphadenectomy in Testicular Cancer
Treatment: a Systematic Review. J Laparoendosc Adv Surg
Tech A 2018;28:682-9.
Williams SB, McDermott DW, Winston D, et al.
Morbidity of open retroperitoneal lymph node dissection
for testicular cancer: contemporary perioperative data.
BJU Int 2010;105:918-21.
Subramanian VS, Nguyen CT, Stephenson AJ, et al.

Transl Androl Urol 2020;9(Suppl 1):S66-S73 | http://dx.doi.org/10.21037/tau.2019.12.36

Translational Andrology and Urology, Vol 9, Suppl 1 January 2020

18.

19.

20.

21.

22.

Complications of open primary and post-chemotherapy
retroperitoneal lymph node dissection for testicular cancer.
Urol Oncol 2010;28:504-9.
Beck SD, Peterson MD, Bihrle R, et al. Short-term
morbidity of primary retroperitoneal lymph node
dissection in a contemporary group of patients. J Urol
2007;178:504-6; discussion 506.
Bhayani SB, Ong A, Oh WK, et al. Laparoscopic
retroperitoneal lymph node dissection for clinical stage I
nonseminomatous germ cell testicular cancer: a long-term
update. Urology 2003;62:324-7.
Neyer M, Peschel R, Akkad T, et al. Long-term results
of laparoscopic retroperitoneal lymph-node dissection
for clinical stage I nonseminomatous germ-cell testicular
cancer. J Endourol 2007;21:180-3.
Poulakis V, Skriapas K, de Vries R, et al. Quality of life
after laparoscopic and open retroperitoneal lymph node
dissection in clinical Stage I nonseminomatous germ cell
tumor: a comparison study. Urology 2006;68:154-60.
Singh A, Chatterjee S, Bansal P, et al. Robot-assisted

S73

23.

24.

25.

26.

retroperitoneal lymph node dissection: Feasibility and
outcome in postchemotherapy residual mass in testicular
cancer. Indian J Urol 2017;33:304-9.
Overs C, Beauval JB, Mourey L, et al. Robot-assisted
post-chemotherapy retroperitoneal lymph node dissection
in germ cell tumor: is the single-docking with lateral
approach relevant? World J Urol 2018;36:655-61.
Busch J, Magheli A, Erber B, et al. Laparoscopic and open
postchemotherapy retroperitoneal lymph node dissection
in patients with advanced testicular cancer--a single center
analysis. BMC Urol 2012;12:15.
Faria EF, Neves HS, Dauster B, et al. Laparoscopic
Retroperitoneal Lymph Node Dissection as a Safe
Procedure for Postchemotherapy Residual Mass in
Testicular Cancer. J Laparoendosc Adv Surg Tech A
2018;28:168-73.
Calestroupat JP, Sanchez-Salas R, Cathelineau X, et al.
Postchemotherapy laparoscopic retroperitoneal lymph
node dissection in nonseminomatous germ-cell tumor. J
Endourol 2009;23:645-50.

Cite this article as: Mittakanti HR, Porter JR. Robot-assisted
laparoscopic retroperitoneal lymph node dissection: a minimally
invasive surgical approach for testicular cancer. Transl Androl
Urol 2020;9(Suppl 1):S66-S73. doi: 10.21037/tau.2019.12.36

© Translational Andrology and Urology. All rights reserved.

Transl Androl Urol 2020;9(Suppl 1):S66-S73 | http://dx.doi.org/10.21037/tau.2019.12.36

